EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects

Detlef Albrecht, Elizabeth Hussey, Richard B Lipton

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70239 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Detlef Albrecht und 2 weiteren Autor:innen. Beteiligte Einrichtung: Satsuma Pharmaceuticals Inc., Durham, NC, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A Inhibitors, Dihydroergotamine, Itraconazole. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Satsuma Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydroergotamine (DHE) prescribing information contains a boxed warning regarding the possibility of serious and/or life‐threatening peripheral ischemia with co‐administration of strong cytochrome P450 3A4 (CYP3A4) inhibitors. The effects of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics and safety of nasally administered STS101 (DHE) were evaluated in this open‐label, 2‐period, fixed sequence study in 31 healthy participants. Following a single dose of 5.2 mg STS101, DHE exposure when co‐administered with itraconazole was 119% and 114% of that when administered alone, for the area under the plasma concentration–time curve from time 0 to infinity (AUC 0–inf ), and maximum observed plasma concentration (C max ), respectively. Co‐administration of STS101 with itraconazole was not associated with an increase in the frequency of treatment emergent adverse events compared with STS101 alone. No clinically significant findings of a single dose of 5.2 mg STS101 alone or with itraconazole were observed on nasal examinations, safety laboratory values, vital signs, or safety electrocardiograms. In this study, no clinically meaningful drug–drug interactions were seen when STS101 was co‐administered with a strong CYP3A4 inhibiting drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3A InhibitorsDihydroergotamineItraconazoleAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, IntranasalAntifungal AgentsArea Under CurveCytochrome P-450 CYP3ADrug InteractionsHealthy VolunteersPowders

Stichwörter der Autor:innen

CYP3A4DHEdihydroergotamine mesylatedrug interactionsintranasalitraconazolemigrainepharmacokinetics

Substanzen

Antifungal AgentsCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDihydroergotamineItraconazolePowders

Autor:innen und Institutionen

  • Satsuma Pharmaceuticals Inc., Durham, NC, USA.
  • Allucent, Cary, NC, USA.
  • Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, NY, USA.

Förderung

  • Satsuma Pharmaceuticals, Inc.

Zitieren

APA

Albrecht, D., Hussey, E., & Lipton, R. B. (2026). An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70239

Vancouver

Albrecht D, Hussey E, Lipton RB. An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70239

BibTeX
@article{Albrecht2026,
  author = {Albrecht, Detlef and Hussey, Elizabeth and Lipton, Richard B},
  title = {An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70239}
}
Kostenlos starten →